HippoScreen's Stress EEG Assessment (SEA) System obtained TFDA Approval

HippoScreen has received Taiwan Food and Drug Administration (TFDA) Class II clearance for the Stress EEG Assessment (SEA) System as Software as a Medical Device (SaMD).  It is the first SaMD to be used as assistance in the diagnosis of Major Depression Disorder.

This marks a siginificant step of the company. We look forward to applying SEA technology to screening more people and help raise public mental health.